Product Description
Fluorouracil is part of a group of chemotherapy drugs known as anti metabolites. Anti metabolites are similar to normal body molecules but they have a slightly different structure.Fluorouracil is also known as FU or 5FU and is one of the most commonly used drugs to treat cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/fluorouracil)
Mechanisms of Action: TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Keratosis | Keratosis, Actinic
Known Adverse Events: Erythema | Keratosis | Pruritus | Keratosis, Actinic | Edema
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, Slovakia, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Adenocarcinoma|Anal Cancer|Bladder Cancer|Breast Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Keratosis, Actinic|Muscle Cancer|Nasopharyngeal Cancer|Neuroendocrine Carcinoma|Pancreatic Cancer|Peritoneal Cancer|Squamous Cell Carcinoma
Phase 2: Anus Cancer|Bile Duct Cancer|Biliary Tract Cancer|Ductal Carcinoma|Hepatocellular Carcinoma|Islet Cell Carcinoma|Liver Cancer|Pancreatic Ductal Carcinoma|Sarcoma
Phase 1: Epilepsy|Muscle Spasticity|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STEREOPAC-001 | P2 |
Unknown Status |
Pancreatic Cancer|Adenocarcinoma |
2032-10-01 |
|
| 2023-509814-12-00 | P2 |
Unknown Status |
Colorectal Cancer |
2031-03-31 |
|
| AndroMETa-GEA | P2 |
Recruiting |
Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer |
2030-10-01 |
|
| ACO/ARO/AIO-18.2 | P3 |
Recruiting |
Colorectal Cancer |
2030-08-01 |